Dr James Callery
James Callery is a British medical doctor who has worked as a Research Physician within the Malaria Department at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand since 2017.
At MORU James has worked as co-investigator and Research Physician on the TACT-CV study, a multicentre therapeutic efficacy and safety trial in Southeast Asia, comparing artemether-lumefantrine (ACT) with artemether-lumefantrine plus amodiaquine (Triple ACT) for the treatment of uncomplicated falciparum malaria. He has been running and monitoring the study sites in Cambodia whilst working in close collaboration with colleagues across the Greater Mekong Subregion (GMS).
With the development and spread of multi-drug resistant malaria parasites, this novel combination therapy could play an important role in the efforts to eliminate malaria from the GMS.
Since 2018, James has also coordinated large public engagement projects in Northeastern Cambodia. These events aim to engage the local community with malaria prevention and other health awareness campaigns.
James’ main research interest is focussed on the development and evaluation of novel malaria intervention strategies to aid elimination efforts in the GMS. The TACT-CV study will be completed in early 2020 and James has already begun work on a new clinical trial evaluating ACTs as malaria prophylaxis in Cambodian forest-goers.
Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning
Das D. et al, (2022), Malaria Journal, 21
Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study
Perrone C. et al, (2022)
Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?
van der Pluijm RW. et al, (2022), The Lancet Infectious Diseases, 22, 765 - 766
Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
Peto TJ. et al, (2022), The Lancet Infectious Diseases, 22, 867 - 878
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-umefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial (vol 22, pg 867, 2022)
Peto TJ. et al, (2022), LANCET INFECTIOUS DISEASES, 22, E128 - E128